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Abstract
Skin and skin structure infection (SSSI) is classified as complicated (cSSSI) if it involves deep subcutaneous tissue or requires
surgery. Factors associated with blood culture sampling and bacteremia have not been established in patients with cSSSI.
Moreover, the benefit of information acquired from positive blood culture is unknown. The aim of this study was to address
these important issues. In this retrospective population-based study from two Nordic cities, a total of 460 patients with cSSSI
were included. Blood cultures were drawn from 258 (56.1%) patients and they were positive in 61 (23.6%) of them. Factors
found to be associated with more blood culture sampling in multivariate analysis were diabetes, duration of symptoms shorter
than 2 days and higher C-reactive protein (CRP) level.Whereas factors associated with less frequent blood culture sampling were
peripheral vascular disease and a surgical wound infection. In patients from whom blood cultures were taken, alcohol abuse was
the only factor associated with culture positivity, as CRP level was not. Patients with a positive blood culture had antibiotic
streamliningmore often than non-bacteremic patients. A high rate of blood culture positivity in patients with cSSSI was observed.
Factors related to more frequent blood culture sampling were different from those associated with a positive culture.
Keywords Skin and soft tissue infection . Cellulitis . C-reactive protein . Bacteremia . Abscess . Bloodstream infection
Introduction
Skin and skin structure infections (SSSIs) are among the most
common bacterial infections in patients presenting in emer-
gency rooms and their incidence is rising [1–3]. In 1998, FDA
classified SSSI as complicated (cSSSI) if it involves deep
subcutaneous tissues or requires surgery [4]. Although initially
designed for the clinical trials, the umbrella term cSSSI is still
useful in the detection of the most severe forms of SSSIs [5].
Blood cultures are not routinely recommended for patients
with SSSI [6, 7]. This is mainly because positive findings have
been rare [8] and have only seldom affected antibiotic treat-
ment [9]. However, this might not be generalizable to all
SSSIs since the rate of bacteremia has been reported to in-
crease in more severe cases. Whereas blood culture positivity
of 4.6% has been reported in erysipelas, it was 7.9% in cellu-
litis [10] and even higher rate of 11.9% was reported in a
recent European survey on cSSSI [11]. Factors associatedwith
bacteremia in cSSSI have not been studied, but in less severe
SSSI comorbidity [12] in another study, up to 11 patient fac-
tors, including male gender and older age, were linked to
bacteremia [13].
We conducted a population-based study including 460 pa-
tients with cSSSI from two Nordic cities and reported that at
least 13.3% of patients had a bloodstream infection with equal
yield of one fourth of samples being positive in both study
sites [14]. Male gender and cellulitis were associated with
blood culture sampling and bacteremia with later clinical sta-
bility [14, 15]. In the present study, we analysed further from
the same real-life setup factors predicting and associated with
blood culture positivity and how the knowledge of blood cul-
ture positivity affected the treatment.
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Materials and methods
The study design was a retrospective observational cohort
study. All adult patients hospitalised for cSSSI within a 4-
year period 2008–2011 in Helsinki University Hospital and
Helsinki City Hospital in Helsinki, Finland (604,000 inhabi-
tants), and Sahlgrenska University Hospital in Gothenburg,
Sweden (525,000 inhabitants), were included in the study
[14]. Patients were recognised using International
Classification of Diseases (ICD-10) codes and demographic
and clinical data were collected from the medical records.
These hospitals have the only emergency departments in their
catchment areas why virtually all hospitalised patients with
cSSSI have been included enabling the population-based ap-
proach . The preva lence of methic i l l in - res is tan t
Staphylococcus aureus was 2.8% in Finland [16] and 0.8%
in Sweden in 2011 [17].
Detailed study protocol is presented in the primary publi-
cation of this study [14]. In short, to be included, patients were
required to have infection affecting deeper soft tissue (e.g.
cellulitis or fasciitis), infection requiring significant surgical
intervention, infection which developed on a lower extremity
in a patient with diabetes mellitus or peripheral vascular dis-
ease or to have a major abscess or an infected ulcer. Patients
also had to have at least one systemic sign of infection: tem-
perature > 38 °C or < 36 °C or white blood cell count >
10,000/mm3 or < 4000/mm3.
Study definitions and statistical analyses
Microbial diagnosis was obtained by blood culture, bacterial
culture of tissue or superficial swabs in routine cultures.
Cellulitis/fasciitis was defined as an infection without abscess,
diabetic foot/leg ulcer or peripheral vascular disease ulcer. The
evaluation of clinical stability was based on improvement of
vital signs and decrease of fever. Streamlining was defined as
change of antibiotic therapy to pathogen specific one.
Microbes from normal cutaneous flora (e.g. coagulase-
negative staphylococci) were generally not considered as
pathogens in blood cultures and an infectious disease special-
ist assessed each case. Antibiotic treatment prescribed before
admission or before the fulfilment of cSSSI criteria during the
hospitalisation was recorded.
Categorical variables were summarised using counts and
percentages. Continuous variables were summarised using
means and standard deviation (SD) or median, interquartile
range (IQR), or range if subgroup was small. In univariate
analysis, the difference between two groups was compared
using chi-square test or Fisher’s exact test, as appropriate.
Continuous variables were analysed using a two-sample t test
or Mann-Whitney U test if variables were not normally dis-
tributed. Odds ratio (OR) was calculated with 95% confidence
interval (CI). Multivariate logistic regression was performed
including variables that were clinically relevant, had univari-
ate p values less than 0.15 and were not multicollinear. P value
< 0.05 was considered significant. SPSS version 22.0 (SPSS
Inc., Chicago, IL, USA) was used for statistical analyses.
Factors associated with blood culture sampling were
analysed also using multivariate logistic regression analysis
and factors associated with bacteremia were analysed by com-
paring blood culture positive patients with blood culture neg-
ative patients. This approach differs from the analysis per-
formed in the previous publications of this material [14, 15].
Results
Blood culture findings
In total, 460 patients with cSSSI were included. Blood cul-
tures were drawn from 258 (51.6%) patients and they were
positive in 61 (23.6%). Although there was some heterogene-
ity in the patient populations between the two centres [18],
proportion of positive blood cultures was almost equal, in
Helsinki 22.9% and 25% in Gothenburg. Blood culture iso-
lates were Streptococcus pyogenes 19 cases (31.1%),
Staphylococcus aureus 19 (31.1%), non-A beta-hemolytic
streptococci 12 (19.7%), Streptococcus pneumoniae 1
(1.6%), Enterobacteriaceae spp. 1 (1.6%), polymicrobial 5
(8.2%) and unknown (4/6.6%).
Factors associated with blood culture sampling
Patients from whom blood cultures were drawn (n = 258)
were compared to those from whom blood cultures were not
drawn (n = 202) for this analysis (Table 1).
In logistic regression analysis, diabetes (OR 1.9, P =
0.008), peripheral vascular disease (OR 0.5, P = 0.007),
post-surgical wound infection (OR 0.4, P = 0.005), symptoms
shorter than 2 days (OR 3.0, P < 0.001) and CRP over
150 mg/L on the first day (OR 1.8, P = 0.006) were signifi-
cantly associated with blood culture sampling (Table 1).
Factors associated with blood culture positivity
To analyse factors associated with blood culture positivity, we
compared patients with a positive blood culture (n = 61) to
patients with a negative blood culture (n = 197).
Results of comparisons between the groups are shown in
Table 2. Neither CRP measured at the time of the diagnosis of
cSSSI nor the highest CRP during the hospital stay was asso-
ciated with blood culture positivity (Table 2). In multivariate
logistic regression analysis, only factor associated significant-
ly with bacteremia was alcohol abuse (OR 5.5, P < 0.001).
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Clinical endpoints in blood culture positivity
Bacteremic patients (n = 61) were less likely to reach clin-
ical stability within 3 days and they were more often ad-
mitted to intensive care unit and had significantly longer
hospital stay than blood culture negative patients (Table 3).
In addition, 23.3% of blood culture positive patients had
antibiotic treatment streamlined as compared to 6.3% of
culture negative patients (P = 0.0002).
Discussion
In this population-based study, we observed that 23.6% of the
cSSSI patients from whom blood culture was taken had bac-
teremia. Streptococci and Staphylococcus aureus
corresponded for 84% of cases. Bacteremia was associated
with later clinical stability, more ICU admissions and more
common streamlining. Higher CRP was linked to more com-
mon blood culture sampling, but not to culture positivity.
Diabetes and duration of symptoms shorter than 2 days were
observed to increase the likelihood of blood culture sampling,
but only alcoholism increased the likelihood of blood culture
positivity.
Blood culture positivity reported here was higher than
11.6% in a multi-centre study from Central and Southern
Europe, which had a sampling rate of 53% [11]. The most
evident explanation is that our patientmaterial wasmore severe.
Blood culture positivity rate in less severe SSSIs like erysipelas
or cellulitis has been reported to be 4.6–9% [10, 19].
In previous study on this patient material, it was observed
that patients who had blood cultures drawn had higher mor-
tality suggesting that clinicians ordered blood cultures from
sicker patients [14]. Although the blood culture drawing rate
differed in the two centres, the rate of positive findings was
equal suggesting that blood cultures should most probably be
taken with lower threshold in cSSSI.
Diabetes and higher CRP provoked clinicians to order
blood culture sampling in accordance with data in erysipelas
[19] and uncomplicated cellulitis [20]. In contrast to one pre-
vious study, prior antibiotic treatment was not negatively as-
sociated with positive blood culture findings but it resulted in
less common (45.3%) sampling than compared to patients
without prior antibiotics (54.7%, P = 0.004) [21]. Alcohol
abuse had a striking association with blood culture positivity,
as of patients with a history of alcohol abuse 53.6% had bac-
teremia as compared to 20% of those who did not. Similarly,
in patients with uncomplicated cellulitis, alcohol abuse was
the only discriminant patient characteristic associated with
bacteremia [20].
Beta-hemolytic streptococci and Staphylococcus aureus
were not only the most common blood culture findings but
they also constituted 64% of all cSSSI cases in which the
aetiology was verified. Whereas we observed only one case
of gram-negative monobacteremia, Van Daalen et al. found
more gram-negative bacteria than Staphylococcus aureus
[12] and Peralta et al. observed a gram-negative aetiology in
24.6% of bacteremias [21]. Accordingly, in a systematic re-
view of patients with cellulitis and erysipelas, gram-negative
bacteria were concluded to be at least as common as S. aureus
in blood cultures in cellulitis [10]. These differences might be
explained by difference in patient selection in these studies.
Our results contradict the view that blood cultures would
not be useful because in complicated cellulitis they rarely had
an effect on antibiotic therapy [9]. In our material, antibiotic
treatment was streamlined more often in bacteremic than in
non-bacteremic patients (23.3% versus 6.3%, P < 0.001).
Accordingly, a change in the antibiotic treatment was recorded
in 49% of patients with lower limb cellulitis after blood culture
results became positive [21]. Furthermore, in countries with
higher antibiotic resistance, the importance of blood culture-
directed therapy has been pointed out [22].
Blood culture positivity was linked to later clinical stability,
which without culture result might lead to a premature change
of antibiotic treatment to more broad-spectrum. However,
Table 3 Outcome of 258 cSSSI patients from whom blood cultures were drawn. Data is shown as number of patients (%) in each column
Variable All (n = 258) Positive blood
cultures (n = 61)
Negative blood
cultures (n = 197)
Odds ratio
(95% CI)
P value
Clinical stability within 3 days (n = 223) 105 (47.1) 15 (30) 90 (52) 0.4 (0.2–0.8) 0.006
Admission to ICU 51 (19.8) 20 (32.8) 31 (15.7) 2.6 (1.4–5.0) 0.003
Surgical intervention after the diagnosis of cSSSI 129 (50) 34 (55.7) 95 (48.2) 1.4 (0.8–2.4) 0.305
30-day mortality 16 (6.2) 4 (6.6) 12 (6.1) 1.1 (0.3–3.5) > 0.999
Streamlining (n = 251) 26 (10.4) 14 (23.3) 12 (6.3) 4.5 (2.0–10.5) < 0.001
Duration of antimicrobial treatment, days
[median (IQR)] (n = 255)
21 (12–38) 26 (11.5–46.8) 20 (12–38) 0.191
Length of hospital stay, days [median (IQR)] (n = 228) 15 (8–29) 19.5 (13–45.3) 13 (7–23) < 0.001
CI confidence interval, IQR interquartile range
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positive blood culture was not linked to longer antibiotic treat-
ment or higher mortality as has been reported previously [11].
The likely explanation to these differences is the low number
of bacteremic patients and virtual lack of gram-negative and
resistant bacteria in our study.
The strength of this study is its population-based nature,
although some patients may have been unrecognised due to
coding inaccuracy. Major limitations of this study are due to
its retrospective nature. Data was collected from medical re-
cords, which left missing data in some parameters. Fifty-six
percent of patients were subjected to blood culture sampling
and were included in the analysis of factors associated with
bacteremia, creating an inevitable selection bias.
In this population-based study in cSSSI, we observed that a
positive blood culture was more common than previously re-
ported and affected 23.6% of patients with blood culture sam-
pled. Factors linked to higher blood culture sampling rate were
not generally related to higher positive finding yield. A clear
benefit of blood culture positivity on patient management was
shown in more frequent antibiotic streamlining and knowl-
edge of later clinical stability.
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